Request a Copy: State of the Market Report
Early Detection Testing for Alzheimer's Disease
Rising dementia rates are a global health trend, and a common theme emerging from Alzheimer's drug trials is the need for earlier detection of disease biomarkers and cognitive symptoms. This report provides a detailed overview of available (and future) testing methods for Alzheimer's and dementia-- these methods can be broadly segmented into brain imaging tests, neurocognitive tests, cerebrospinal fluid (CSF) tests, genetic tests, and the future possibility of blood serum tests. Representative companies providing these testing products include GE Healthcare (GE), Philips (PHG) Siemens (SI), Positron Corporation (POSC), NeuroTrax, and CogState (CGS.AX).
A snapshot of Alzheimer's drug candidates currently in clinical trials is also included in the report. An email with download link will be sent after submitting the request form below.